Advances in population pharmacokinetics of meropenem in critically ill adult patients
- VernacularTitle:美罗培南在成人重症感染患者中的群体药动学研究进展
- Author:
Guiqin XU
1
;
Delong DUO
2
;
Ni ZHAO
2
;
Ya’e CHANG
2
;
Zhilan HUAN
2
;
Xue WU
2
;
Yafeng WANG
2
Author Information
1. College of Pharmacy，Qinghai University，Xining 810016，China;Dept. of Pharmacy，Qinghai Provincial People’s Hospital，Xining 810007，China
2. Dept. of Pharmacy，Qinghai Provincial People’s Hospital，Xining 810007，China
- Publication Type:Journal Article
- Keywords:
severe infection;
meropenem;
population pharmacokinetics;
drug administration plan
- From:
China Pharmacy
2025;36(22):2873-2878
- CountryChina
- Language:Chinese
-
Abstract:
Meropenem （MEM） is one of the important drugs for the treatment of severe infections， but the standard dose is often difficult to achieve an effective therapeutic concentration target. This article reviews the related studies on the population pharmacokinetics of MEM in patients with severe infection. It is found that the apparent volume of distribution （Vd） and clearance rate are the most important factors affecting the dose adjustment， and the factors affecting Vd include serum albumin， age， overall weight， shock status， and chest/abdomen/cerebrospinal fluid drainage. The main factors affecting the clearance rate were renal function， renal replacement therapy treatment mode and combination therapy. For adult patients with severe infections in China， MEM is recommended to be administered in an individualized manner based on glomerular filtration rate， with a dosage range of 500 to 1 500 mg given every 4 to 6 hours， and prolonged infusion is preferred. When the minimum inhibitory concentration （MIC） of the pathogenic bacteria reaches 64 mg/L， therapeutic drug monitoring is required. For therapeutic efficacy， it is essential to ensure that the trough concentration remains above the MIC； to prevent drug resistance， it should be maintained above 4×MIC. Regarding safety， it is recommended that the upper limit of the trough concentration be 32 mg/L， and blood sampling for monitoring can be conducted as early as after 1 to 2 doses of administration.
